MEI Pharma to Host Analyst & Investor Event
Live Webcast from San Francisco on December 8th
Dec 1, 2014
SAN DIEGO, Dec. 1, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its 2nd Annual Analyst and Investor Event on Monday, December 8, 2014 at 6:00 p.m. Pacific time at the Westin St. Francis in San Francisco. The event will feature a clinical update by Robert D. Mass, MD, Chief Medical Officer of MEI Pharma, along with a presentation by Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center. A live webcast of the event can be accessed at www.meipharma.com. A replay will be available approximately one hour after its conclusion.
Interim data from an open-label Phase II clinical study of the Company's lead investigational drug candidate Pracinostat in combination with azacitidine in elderly patients with newly diagnosed AML will be presented at the American Society of Hematology Annual Meeting on Saturday, December 6, 2014 at 5:30 p.m. Pacific time from Hall E in the North Building of the Moscone Center in San Francisco. A copy of the poster, entitled "Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)," will also be available at www.meipharma.com.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor currently being developed for myelodysplastic syndrome (MDS) and AML. In August 2014, the Company completed enrollment in a randomized, placebo-controlled Phase II study of Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk MDS. The Company plans to unblind the study and report topline data in Q1 2015. MEI Pharma is also developing ME-344, a mitochondrial inhibitor currently in a Phase Ib study in combination with topotecan in patients with small cell lung or ovarian cancer who failed initial therapy. In September 2013, the Company further expanded its pipeline of drug candidates with the acquisition of PWT143, a highly selective PI3K delta inhibitor. For more information, go to www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
SOURCE MEI Pharma, Inc.
For further information: Pete De Spain, Vice President, Investor Relations & Corporate Communications, (858) 792-3729, email@example.com